(LLY) Eli Lilly - Ratings and Ratios
Diabetes Treatments, Cancer Medications, Immunology Drugs
LLY EPS (Earnings per Share)
LLY Revenue
Description: LLY Eli Lilly
Eli Lilly and Company is a leading pharmaceutical company that develops and markets a diverse portfolio of human pharmaceuticals globally. The companys product portfolio includes a range of diabetes treatments, such as Basaglar, Humalog, and Trulicity, as well as oncology products like Alimta, Cyramza, and Verzenio. Additionally, Eli Lilly offers treatments for various other conditions, including rheumatoid arthritis, psoriasis, and obesity.
From a business perspective, Eli Lilly has established collaborations with several companies, including Incyte Corporation, Boehringer Ingelheim Pharmaceuticals, and F. Hoffmann-La Roche Ltd, to advance its research and development capabilities. The companys strong research pipeline and strategic partnerships are key drivers of its growth. Key Performance Indicators (KPIs) such as Revenue Growth Rate, Research and Development (R&D) expenditure as a percentage of revenue, and Product Approval Rate are crucial in evaluating the companys performance.
In terms of financial performance, Eli Lillys Market Capitalization stands at approximately $711.9 billion, indicating its significant presence in the pharmaceutical industry. The companys Return on Equity (RoE) of 76.92% suggests a strong ability to generate profits from shareholder equity. Other relevant KPIs include the companys Debt-to-Equity Ratio, Operating Margin, and Earnings Per Share (EPS) growth rate, which can provide insights into its financial health and profitability.
To further analyze Eli Lillys stock performance, technical indicators such as the Relative Strength Index (RSI), Bollinger Bands, and Moving Averages can be used. For instance, the companys current price is near its support level of $798.1, and the SMA20 is above the SMA50, indicating a potential bullish trend. However, the SMA200 is above the current price, suggesting a potential resistance level.
LLY Stock Overview
| Market Cap in USD | 677,175m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 1978-01-13 |
LLY Stock Ratings
| Growth Rating | 35.3% |
| Fundamental | 75.4% |
| Dividend Rating | 66.0% |
| Return 12m vs S&P 500 | -31.3% |
| Analyst Rating | 4.24 of 5 |
LLY Dividends
| Dividend Yield 12m | 0.75% |
| Yield on Cost 5y | 4.02% |
| Annual Growth 5y | 11.93% |
| Payout Consistency | 99.5% |
| Payout Ratio | 35.9% |
LLY Growth Ratios
| Growth Correlation 3m | -71% |
| Growth Correlation 12m | -59.8% |
| Growth Correlation 5y | 95.6% |
| CAGR 5y | 36.37% |
| CAGR/Max DD 3y | 1.05 |
| CAGR/Mean DD 3y | 7.77 |
| Sharpe Ratio 12m | 1.02 |
| Alpha | -35.23 |
| Beta | 0.782 |
| Volatility | 28.75% |
| Current Volume | 2790.9k |
| Average Volume 20d | 3222.5k |
| Stop Loss | 725.7 (-3%) |
| Signal | 0.49 |
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income (13.80b TTM) > 0 and > 6% of Revenue (6% = 3.20b TTM) |
| FCFTA 0.00 (>2.0%) and ΔFCFTA 4.80pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 20.34% (prev 7.92%; Δ 12.42pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.11 (>3.0%) and CFO 10.94b <= Net Income 13.80b (YES >=105%, WARN >=100%) |
| Net Debt (36.53b) to EBITDA (19.66b) ratio: 1.86 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.28 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (899.8m) change vs 12m ago -0.49% (target <= -2.0% for YES) |
| Gross Margin 82.64% (prev 80.75%; Δ 1.89pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 61.64% (prev 54.15%; Δ 7.49pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 19.52 (EBITDA TTM 19.66b / Interest Expense TTM 910.1m) >= 6 (WARN >= 3) |
Altman Z'' 2.83
| (A) 0.11 = (Total Current Assets 49.85b - Total Current Liabilities 39.02b) / Total Assets 100.92b |
| (B) 0.17 = Retained Earnings (Balance) 17.38b / Total Assets 100.92b |
| (C) 0.21 = EBIT TTM 17.77b / Avg Total Assets 86.40b |
| (D) 0.17 = Book Value of Equity 14.25b / Total Liabilities 82.57b |
| Total Rating: 2.83 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 75.35
| 1. Piotroski 6.0pt = 1.0 |
| 2. FCF Yield 0.06% = 0.03 |
| 3. FCF Margin 0.78% = 0.19 |
| 4. Debt/Equity 2.18 = 0.49 |
| 5. Debt/Ebitda 2.03 = -0.06 |
| 6. ROIC - WACC 20.43% = 12.50 |
| 7. RoE 88.36% = 2.50 |
| 8. Rev. Trend 96.50% = 4.83 |
| 9. Rev. CAGR 34.11% = 2.50 |
| 10. EPS Trend 54.79% = 1.37 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of LLY shares?
Over the past week, the price has changed by +1.29%, over one month by +6.70%, over three months by -7.15% and over the past year by -18.37%.
Is Eli Lilly a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of LLY is around 810.29 USD . This means that LLY is currently overvalued and has a potential downside of 8.3%.
Is LLY a buy, sell or hold?
- Strong Buy: 16
- Buy: 7
- Hold: 4
- Sell: 1
- Strong Sell: 1
What are the forecasts/targets for the LLY price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 891.6 | 19.2% |
| Analysts Target Price | 891.6 | 19.2% |
| ValueRay Target Price | 902.9 | 20.7% |
Last update: 2025-09-13 05:03
LLY Fundamental Data Overview
CCE Cash And Equivalents = 3.55b USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 49.4365
P/E Forward = 25.0627
P/S = 12.715
P/B = 37.1026
P/EG = 0.8279
Beta = 0.465
Revenue TTM = 53.26b USD
EBIT TTM = 17.77b USD
EBITDA TTM = 19.66b USD
Long Term Debt = 34.18b USD (from longTermDebt, last quarter)
Short Term Debt = 5.72b USD (from shortTermDebt, last quarter)
Debt = 39.90b USD (Calculated: Short Term 5.72b + Long Term 34.18b)
Net Debt = 36.53b USD (from netDebt column, last quarter)
Enterprise Value = 713.53b USD (677.17b + Debt 39.90b - CCE 3.55b)
Interest Coverage Ratio = 19.52 (Ebit TTM 17.77b / Interest Expense TTM 910.1m)
FCF Yield = 0.06% (FCF TTM 414.3m / Enterprise Value 713.53b)
FCF Margin = 0.78% (FCF TTM 414.3m / Revenue TTM 53.26b)
Net Margin = 25.91% (Net Income TTM 13.80b / Revenue TTM 53.26b)
Gross Margin = 82.64% ((Revenue TTM 53.26b - Cost of Revenue TTM 9.25b) / Revenue TTM)
Tobins Q-Ratio = 50.06 (Enterprise Value 713.53b / Book Value Of Equity 14.25b)
Interest Expense / Debt = 0.62% (Interest Expense 249.0m / Debt 39.90b)
Taxrate = 16.49% (2.09b / 12.68b)
NOPAT = 14.84b (EBIT 17.77b * (1 - 16.49%))
Current Ratio = 1.28 (Total Current Assets 49.85b / Total Current Liabilities 39.02b)
Debt / Equity = 2.18 (Debt 39.90b / last Quarter total Stockholder Equity 18.27b)
Debt / EBITDA = 2.03 (Net Debt 36.53b / EBITDA 19.66b)
Debt / FCF = 96.32 (Debt 39.90b / FCF TTM 414.3m)
Total Stockholder Equity = 15.62b (last 4 quarters mean)
RoA = 13.67% (Net Income 13.80b, Total Assets 100.92b )
RoE = 88.36% (Net Income TTM 13.80b / Total Stockholder Equity 15.62b)
RoCE = 35.68% (Ebit 17.77b / (Equity 15.62b + L.T.Debt 34.18b))
RoIC = 28.86% (NOPAT 14.84b / Invested Capital 51.41b)
WACC = 8.43% (E(677.17b)/V(717.08b) * Re(8.90%)) + (D(39.90b)/V(717.08b) * Rd(0.62%) * (1-Tc(0.16)))
Shares Correlation 3-Years: -53.44 | Cagr: -0.04%
Discount Rate = 8.90% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 66.67% ; FCFE base≈414.3m ; Y1≈272.0m ; Y5≈124.4m
Fair Price DCF = 2.37 (DCF Value 2.13b / Shares Outstanding 896.5m; 5y FCF grow -40.0% → 3.0% )
Revenue Correlation: 96.50 | Revenue CAGR: 34.11%
Rev Growth-of-Growth: 4.46
EPS Correlation: 54.79 | EPS CAGR: 0.0%
EPS Growth-of-Growth: 97.24
Additional Sources for LLY Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle